Oral Microbiology Immunology 2006: 21: 1–5
Printed in Singapore. All rights reserved

ORAL MICROBIOLOGY
AND IMMUNOLOGY

Absence of *Helicobacter pylori* in the oral cavity of 10 non-dyspeptic subjects demonstrated by real-time polymerase chain reaction

J. Martinez-Gomis[1,2], A. Diouf[1,3], N. Lakhssassi[1], M. Sixou[1]

[1]Département d'Epidemiologie des Maladies Infectieuses, Faculté de Chirurgie Dentaire, Université Paul-Sabatier, Toulouse, France, [2]Department of Prosthodontics, Faculty of Dnetistry, University of Barcelona, Barcelona, Spain, [3]Département d'Odontologie, Faculté de Médecine Pharmacie et Odonto-Stomatologie, Université Cheikh Anta DIOP, Dakar, Senegal

Martinez-Gomis J, Diouf A, Lakhssassi N, Sixou M. Absence of Helicobacter pylori *in the oral cavity of 10 non-dyspeptic subjects demonstrated by real-time polymerase chain reaction.*
Oral Microbiol Immunol 2006: 21: 1–5. © Blackwell Munksgaard, 2006.

Background/aims: *Helicobacter pylori* plays a significant role in gastric disease. However, the presence of this bacterium in the oral cavity remains controversial. The aim of the present study was to detect and quantify *H. pylori* in 29 different sites of the oral cavity in non-dyspeptic subjects by means of real-time polymerase chain reactions (PCR).
Methods: Ten subjects without gastric symptoms were studied. Samples from unstimulated saliva, three sites of the tongue, oral mucosa, and 12 sites of both supragingival and subgingival plaque were collected from each subject. DNA was extracted from the oral samples and analysed for the presence of *H. pylori* by real-time PCR (LightCycler®) using JW23/22 primers which targeted the 16S rRNA gene. DNA from *H. pylori* DSM 4867 was used as a positive control. Relative quantification with external standards was performed by calculating the target to reference ratio.
Results: Amplification efficiency for the LightCycler® 2.0 runs ranged from 1.8 to 2.4. Melting curve analysis identified all the positive control capillaries, which contained *H. pylori* reference DNA, as a single and narrow peak at a melting temperature between 84.5 and 84.9°C. All the negative control capillaries with no template control and the 29 oral samples from each subject showed either no melting peaks or broad melting peaks below 80°C, which were considered as primer dimers. Therefore, *H. pylori* was not detected from any of the 290 oral samples.
Conclusion: *Helicobacter pylori* seems not to be permanently present in the oral cavity of a non-dyspeptic population.

Key words: dental plaque; *Helicobacter pylori*; mucosa; real-time polymerase chain reaction; saliva; tongue

Michel Sixou, Département d'Epidemiologie des Maladies Infectieuses, Faculté de Chirurgie Dentaire, Université Paul-Sabatier, 3, Chemin des Maraîchers, 31062 Toulouse, France
Tel.: +33 5 62 17 29 60;
fax: +33 5 62 57 13 57;
e-mail: sixou@cict.fr
Accepted for publication March 8, 2006

Helicobacter pylori is a gram-negative, curved, microaerophilic organism that has been implicated in the aetiology of gastritis, in the process of gastric and duodenal ulcer formation, and in gastric cancer (15, 17). Approximately 10% of individuals are affected by gastritis and/or gastric ulcer during their lifetime and over 50% of the world's population carries this infection (7). The prevalence of gastric *H. pylori* infection depends on age and varies strongly between developing and developed countries, and according to ethnicity, place of birth and socioeconomic factors among people living in the same country

(22). The mode of transmission of *H. pylori* is poorly understood, although the oral–oral, gastric–oral and faecal–oral routes are all possible. The natural reservoir for *H. pylori* is unknown. Results of several studies have suggested that the oral cavity may be a reservoir for *H. pylori*, although there are studies that do not support this hypothesis. A literature review thus failed to find evidence supporting the role of the oral cavity as a significant reservoir of *H. pylori* (7, 14, 20). If the oral cavity is a reservoir for *H. pylori*, it is unclear whether it is a permanent or a transient reservoir (7). Although the oral cavity may be a potential source for recrudescence of gastric infection after successful therapy, no study has demonstrated the clinical relevance of this source (10). While it has been suggested that *H. pylori* has a distinct distribution within the oral cavity (30), its specific niche has not yet been identified (7).

Generally, three methods have been used to detect *H. pylori* in the oral cavity (7):

- The rapid urease test or *Campylobacter*-like organism test (CLO test) detects urease produced by microorganisms. Although the only urease-positive bacterium known to reside in the stomach is *H. pylori*, in the oral cavity there are several urease-producing species (such as *Streptococcus* spp.) so the potential for false-positive results is considerable.
- Culture should be the gold standard for the diagnosis of *H. pylori* in the oral cavity. However, the complexity of oral microflora together with the fastidious nature of *H. pylori* can explain the relatively limited success in culturing this bacterium from oral samples.
- Polymerase chain-reaction (PCR) allows rapid detection of even small numbers of specific bacteria within a sample. By this method, *H. pylori* has been detected more frequently in oral samples but results show a great variation as the published reviews point out (7, 14, 20). Recent studies using conventional PCR still report very variable results, with a detection rate ranging from 0% to 100% (1, 5, 8, 9, 11, 31–33). These discrepancies can be explained by differences in the study populations, oral sample collection methods and laboratory detection procedures.

Therefore, the most appropriate method for detection of oral *H. pylori* has yet to be established (7). Real-time PCR has proved to be the most accurate method for *H. pylori* detection in gastric biopsies because of its high specificity, short working time, low risk of contamination, and the fact that it yields a quantitative analysis (26). To our knowledge no study has used real-time PCR to detect *H. pylori* in the oral cavity. Hence, the aim of the present study was to investigate the presence of *H. pylori* at 29 different sites in the oral cavities of 10 healthy subjects, using real-time PCR (LightCycler® 2.0).

Materials and methods

Ten subjects from the Dental School of Toulouse University (France) without gastric symptoms (five men aged 27–53 years, mean age 36.2, and five women aged 26–38 years, mean age 30.4) were studied. The subjects presented neither gingivitis nor periodontal disease and had not used any kind of oral rinses and/or systemic drugs within the previous 4 weeks. All were informed of the study and each signed the informed consent form approved by the local ethics committee.

Subjects were instructed to avoid oral hygiene in the morning and did not smoke. Unstimulated saliva samples from each subject were collected in sterile Falcon polypropylene tubes. An oral mucosa swab was taken from each of four oral sites (dorsum of tongue, right and left lateral tongue, lingual tonsil, and right and left cheek) using a plain sterile swab (Copan®, Brescia, Italy). To collect the supragingival plaque, the targeted regions were first isolated with cotton rolls and air-dried to avoid contamination by bacteria from the oral fluid. Then, supragingival plaque was collected from the buccal and lingual surfaces of 12 different teeth (16, 26, 36, 46, 14, 24, 34, 44, 12, 22, 32, 42) using a plain sterile swab (Copan®). After collection of supragingival plaque, subjects were instructed to brush their teeth to avoid supragingival plaque contamination. Afterwards, subgingival plaque samples were collected from the teeth that had been used for the supragingival samples (12 samples/subject) by means of four sterile paper points (at mesial, distal, buccal and lingual sulcus) left in place for 20 s. All samples were coded and analyses were performed blind.

Helicobacter pylori strain DSM 4867 (CIP 103995-T, ATCC 43504, NCTC 11637) was used as a reference strain. The bacteria were grown in brain–heart infusion agar supplemented with 5% (volume/volume) defibrinated sheep blood. Plates were incubated micro-aerobically (CampyPak®) at 37°C for 5–7 days. Colonies of *H. pylori* were identified by colony morphology, microscopy, Gram-stain and positive reactions for catalase, oxidase and urease. Genomic DNA was obtained from *H. pylori* culture and from oral samples by the High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions.

The assay was performed in the LightCycler® 2.0 real-time PCR instrument (Roche Diagnostics GmbH) in the SYBR Green I format which was targeted at the 16S rRNA gene. The primers used were JW23/22 (9, 23): forward primer 5′-GAG CGC GTA GGC GGG ATA GTC-3′; nucleotides 536 to 556 in GenBank sequence accession no. U01330, reverse primer 5′-CGT TAG CTG CAT TAC TGG AGA-3′; nucleotides 830 to 810 in GenBank no. U01330 (Proligo® Primers&Probes, Paris, France). Each nucleotide sequence was evaluated on-line using the BLAST nucleotide algorithm to verify specificity (3). Serial 10-fold dilutions of DNA extracted from *H. pylori* strain DSM 4867 were used as standards to determine the efficiency of each assay and were included in every set of reactions as a positive control. Negative control reactions with no added template DNA were also used in each set of reactions. A titration experiment was performed using different primers and $MgCl_2$ concentrations and the optimal amplification results for real-time PCR were achieved with 0.8 μM of primer and 4 mM $MgCl_2$. Samples were processed using a LightCycler-FastStart DNA Master SYBR Green I kit (Roche Diagnostics GmbH) with 6.6 μl pure water, 2.4 μl $MgCl_2$ (at a final concentration of 4.0 mM), 2 μl of each primer (at final concentration of 0.8 μM), 2 μl Mix-Taq, and 5 μl DNA sample. The assay was run using the cycling conditions shown in Table 1.

Melting curves were plotted automatically and analysed with the LightCycler® 2.0 software. Since the melting temperature (T_m) of reference *H. pylori* DNA for the 16S rRNA assay was about 84.5–85°C in preliminary experiments, samples were considered positive for the presence of *H. pylori* DNA when a T_m of about 84–85.5°C was obtained. As suggested in Roche's Technical notes, samples exhibiting broader peaks with a T_m below 80°C were considered as primer dimers or non-specific products. Relative quantification with external standards was performed by calculating the target to reference ratio using the crossing point values from the amplification curves.

Table 1. Cycle programs and temperature profile used on the LightCycler instrument for the SYBR Green I format

Program	No. of cycles	Analysis mode	Segment	Target (°C)	Hold time	Slope (°C/s)	Acquisition mode
Denaturation	1	None		95	10:00	20	None
Amplification	45	Quantification	Denaturation	95	00:15	20	None
			Annealing	66	00:10	20	None
			Extension	73	00:25	20	Single
Melting curve	1	Melting curves	Denaturation	95	00:02	20	None
			Annealing	66	00:20	20	Continuous
			Extension	95	00:00	0.1	None
Cooling	1	None		40	01:30	20	None

Results

Amplification efficiencies for the LightCycler® 2.0 runs were very close to 2, ranging from 1.8 to 2.4, which implied a doubling of the amplification product at every cycle (Fig. 1). Since a SYBR Green I-format method cannot distinguish specific from non-specific amplification products, an additional dissociation curve analysis was performed (Fig. 2). The negative first derivative of the fluorescence change is displayed by the instrument as the melting curve with a peak that indicates the melting temperature.

Melting curve analysis identified all the positive control capillaries, containing *H. pylori* reference DNA, as a single, narrow peak at a melting temperature between 84.6 and 84.9°C. All the negative control capillaries with no control template and the 29 oral samples from each subject showed either no melting peaks or broad melting peaks <80°C which were considered as primer dimers. Therefore, the 16S rRNA gene of *H. pylori* was not detected in any of the 290 oral samples of non-dyspeptic subjects. Consequently, quantification or comparison between different sites was not considered useful.

Discussion

Real-time PCR did not reveal *H. pylori* DNA in any oral sample from non-dyspeptic subjects. This is in agreement with other studies using conventional PCR in a non-dyspeptic population (4, 18). Microscopic appearance and the *Campylobacter*-like organisms test provide low specificity in the detection of *H. pylori* in oral samples (7). Detection of oral *H. pylori* from patients with or without gastric symptoms by culture had little success in many studies. Some explanations have been reported: the complexity of the oral microflora, which might inhibit *H. pylori* growth (12), the fastidious growth nature of *H. pylori*, the difficulty in obtaining an appropriate selective medium, the presence of an unculturable but viable coccoid form, a low number of *H. pylori* cells present in the oral samples, and finally the fact that *H. pylori* may not normally be resident in the oral cavity (7, 14, 20). PCR is an extremely sensitive technique that is able to detect one copy of the target DNA fragment and obviates the need for viable organisms. However, two limitations of conventional PCR are the susceptibility of the process to contamination and the impossibility of quantification. Real-time PCR offers many advantages over conventional PCR, such as elimination of post-amplification handling steps and a high degree of sensitivity, specificity and reproducible quantification. Using conventional PCR, a great variation in the prevalence of oral *H. pylori* has been reported, probably as the result of large differences in study populations, oral sample collection, and laboratory detection procedures (7).

The population of the present study was young, lived in a developed country, and was without periodontal disease or gastric symptoms. No *H. pylori* was detected in the oral cavity of ten subjects. If there were a relationship between oral and gastric *H. pylori* infection, one would expect older people, living in developing countries and having gastric symptoms to have higher oral *H. pylori* prevalence. Using conventional PCR, no clear association between age, country, periodontal disease and gastric symptoms with prevalence of oral *H. pylori* was observed in various studies (4, 6, 7, 9, 14, 20, 23, 32). Therefore, comparisons of the prevalence and quantity of oral *H. pylori* between subjects with and without gastric symptoms, with and without periodontal disease, and in developing and developed countries could be the subjects of future research using a real-time PCR.

If the oral cavity were a permanent reservoir for *H. pylori*, a specific niche would exist. Therefore the type and the site of oral sampling are likely to influence the prevalence found for oral *H. pylori*. Whereas in some studies *H. pylori* was found to be more prevalent in dental plaque than saliva or oral mucosa (2, 9, 11, 21, 30), others reported the same or a smaller percentage in dental plaque and saliva or oral mucosa (16, 18, 19, 32). This random distribution within various ecological niches is more consistent with occasional gastric reflux than with permanent oral colonization (14). One of the aims of the present study was to find the oral niche for *H. pylori*. However, it was not found at

LOW RESOLUTION COLOUR FIG



4 *Fig. 1.* Real-time PCR amplification of the two 10-fold dilutions of reference *Helicobacter pylori* DNA (green lines), negative control (blue line), and oral samples. The reaction was monitored with SYBR Green I.

BAD QUALITY COLOUR FIG



4 *Fig. 2.* Identification of 16S rRNA gene in *Helicobacter pylori* by real-time PCR melting curve analysis. The upper graph shows fluorescence versus temperature 'melting curves'. For the two 10-fold dilutions of reference *H. pylori* DNA (green lines), the SYBR Green I Dye fluorescence declined linearly with increasing temperature, followed by a steep decline in fluorescence as the specific product melted (around 85°C). The primer dimers and non-specific products produced in most of the oral samples melted at a much lower temperature. The lower graph shows the negative derivative of fluorescence with respect to temperature, converting melting curves into melting peaks. Melting temperatures of two 10-fold dilutions of reference *H. pylori* DNA (green lines) are between 84.6 and 84.9°C. Melting temperatures of negative control (blue line), and oral samples are <80°C and considered to be primer dimers.

any site of the mucosa, saliva, supra- or subgingival plaque in healthy subjects. It is likely that *H. pylori* is a transient member of the oral microflora of specific populations. Longitudinal studies are needed to investigate the behaviour of this bacterium in the oral cavity over time.

The laboratory procedures play an important role in the sensitivity and specificity of PCR detection of *H. pylori* (7). Melting curve analysis performed by LightCycler® 2.0 resolves PCR products by GC content and length, whereas electrophoresis separates only by length (25). Therefore real-time PCR might have more specificity than conventional PCR. The possibility exists that the primers used in the studies that found a high oral *H. pylori* prevalence amplified the DNA of another bacterium. The choice of the primers is crucial to the sensitivity and specificity of the detection of *H. pylori* both in gastric samples (13, 27) and oral samples (28). Primers directed at the *H. pylori* 16S rRNA gene are very specific, showing a 100% positive predictive value for gastric samples (13). In the present study, primer JW23/22 was chosen to target the 16S rRNA gene, which exhibited a full sensitivity and has been used successfully by other authors (9, 23). Moreover, the BLAST search for the nucleotide sequence showed an extreme specificity for several strains of *Helicobacter*. This fact was verified in our laboratory in a preliminary study, which showed no reactivity of these primers with the DNA of three bacteria (*Bacillus stearothermophilus*, *Escherichia coli* and *Streptococcus mutans*). Nevertheless, according to Technical Note No. LC 1/update 2002 (24), a decrease in the sensitivity produced by enzymatic inhibitors and/or the presence of primer dimers cannot be ruled out.

Song et al. (29) established a competitive PCR assay for the quantification of *H. pylori* organisms in dental plaque samples and found a very low number of the bacteria. Moreover, the presence of very few organisms of both rod and coccoid forms of *H. pylori* in dental plaque was demonstrated by scanning electron microscopy (34). Real-time PCR quantifies the concentration of DNA from the determination of the crossing point value. This was one of the aims of the present study, but could not be performed because none of the 290 oral samples was positive for *H. pylori*.

Although the sample size in the present study was small, *H. pylori* does not seem to be permanently present in the oral cavity of the non-dyspeptic population. Further studies are needed to evaluate the prevalence of *H. pylori* in the oral cavity of subjects with gastric symptoms and/or periodontal disease, using real-time PCR.

References

1. Adler I, Denninghoff VC, Alvarez MI, Avagnina A, Yoshida R, Elsner B. *Helicobacter pylori* associated with glossitis and halitosis. Helicobacter 2005: **10**: 312–317.
2. Allaker RP, Young KA, Hardie JM, Domizio P, Meadows NJ. Prevalence of *Helicobacter pylori* at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission. J Med Microbiol 2002: **51**: 312–317.
3. Altschul SF, Madden TL, Schaffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997: **25**: 3389–3402.
4. Asikainen S, Chen C, Slots J. Absence of *Helicobacter pylori* in subgingival samples determined by polymerase chain reaction. Oral Microbiol Immunol 1994: **9**: 318–320.
5. Bonamico M, Strappini PM, Bonci E et al. Evaluation of stool antigen test, PCR on oral samples and serology for the noninvasive detection of *Helicobacter pylori* infection in children. Helicobacter 2004: **9**: 69–76.
6. Dore-Davin C, Heitz M, Yang H, Herranz M, Blum AL, Corthesy-Theulaz I. *Helicobacter pylori* in the oral cavity reflects handling of contaminants but not gastric infection. Digestion 1999: **60**: 196–202.
7. Dowsett SA, Kowolik MJ. Oral *Helicobacter pylori*: can we stomach it? Crit Rev Oral Biol Med 2003: **14**: 226–233.
8. Fritscher AM, Cherubini K, Chies J, Dias AC. Association between *Helicobacter pylori* and recurrent aphthous stomatitis in children and adolescents. J Oral Pathol Med 2004: **33**: 129–132.
9. Gebara EC, Pannuti C, Faria CM, Chehter L, Mayer MP, Lima LA. Prevalence of *Helicobacter pylori* detected by polymerase chain reaction in the oral cavity of periodontitis patients. Oral Microbiol Immunol 2004: **19**: 277–280.
10. Gisbert JP. The recurrence of *Helicobacter pylori* infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005: **100**: 2083–2099.
11. Kignel S, Almeida Pina F, Andre E, Alves Mayer M, Birman E. Occurrence of *Helicobacter pylori* in dental plaque and saliva of dyspeptic patients. Oral Dis 2005: **11**: 17–21.
12. Krausse R, Piening K, Ullmann U. Inhibitory effects of various micro-organisms on the growth of *Helicobacter pylori*. Lett Appl Microbiol 2005: **40**: 81–86.
13. Lu JJ, Perng CL, Shyu RY et al. Comparison of five PCR methods for detection of *Helicobacter pylori* DNA in gastric tissues. J Clin Microbiol 1999: **37**: 772–774.

14. Madinier IM, Fosse TM, Monteil RA. Oral carriage of *Helicobacter pylori*: a review. J Periodontol 1997: **68**: 2–6.
15. Malfertheiner P, Sipponen P, Naumann M et al. *Helicobacter pylori* eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005: **100**: 2100–2115.
16. Mapstone NP, Lynch DA, Lewis FA et al. Identification of *Helicobacter pylori* DNA in the mouths and stomachs of patients with gastritis using PCR. J Clin Pathol 1993: **46**: 540–543.
17. Marshall BJ, Warren JR. Unidentified 3 curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984: **8390**: 1311–1315.
18. Miyabayashi H, Furihata K, Shimizu T, Ueno I, Akamatsu T. Influence of oral *Helicobacter pylori* on the success of eradication therapy against gastric *Helicobacter pylori*. Helicobacter 2000: **5**: 30–37.
19. Namavar F, Roosendaal R, Kuipers EJ et al. Presence of *Helicobacter pylori* in the oral cavity, oesophagus, stomach and faeces of patients with gastritis. Eur J Clin Microbiol Infect Dis 1995: **14**: 234–237.
20. Nguyen AM, el-Zaatari FA, Graham DY. *Helicobacter pylori* in the oral cavity. A critical review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995: **79**: 705–709.
21. Oshowo A, Tunio M, Gillam D et al. Oral colonization is unlikely to play an important role in *Helicobacter pylori* infection. Br J Surg 1998: **85**: 850–852.
22. Perez-Perez GI, Rothenbacher D, Brenner H. Epidemiology of *Helicobacter pylori* infection. Helicobacter 2004: **9** (S1): 1–6.
23. Riggio MP, Lennon A. Identification by PCR of *Helicobacter pylori* in subgingival plaque of adult periodontitis patients. J Med Microbiol 1999: **48**: 317–322.
24. Roche® Molecular Biochemicals. Technical Note No. LC 1/update 2002 [WWW document]. URL http://www.roche-applied-science.com/sis/rtpcr/lightcycler/ [accessed on ddmmyy].
25. Roche® Molecular Biochemicals. Technical Note No. LC 9/2000 [WWW document]. URL http://www.roche-applied-science.com/sis/rtpcr/lightcycler/ [accessed on ddmmyy].
26. Ruzsovics A, Molnar B, Tulassay Z. Review article: Deoxyribonucleic acid-based diagnostic techniques to detect *Helicobacter pylori*. Aliment Pharmacol Ther 2004: **19**: 1137–1146.
27. Smith SI, Oyedeji KS, Arigbabu AO et al. Comparison of three PCR methods for detection of *Helicobacter pylori* DNA and detection of cagA gene in gastric biopsy specimens. World J Gastroenterol 2004: **10**: 1958–1960.
28. Song Q, Haller B, Schmid RM, Adler G, Bode G. *Helicobacter pylori* in dental plaque: a comparison of different PCR primer sets. Dig Dis Sci 1999: **44**: 479–484.
29. Song Q, Haller B, Ulrich D, Wichelhaus A, Adler G, Bode G. Quantitation of *Helicobacter pylori* in dental plaque samples by competitive polymerase chain reaction. J Clin Pathol 2000: **53**: 218–222.
30. Song Q, Lange T, Spahr A, Adler G, Bode G. Characteristic distribution pattern of *Helicobacter pylori* in dental plaque and saliva detected with nested PCR. J Med Microbiol 2000: **49**: 349–353.
31. Tiwari SK, Khan AA, Ahmed KS et al. Polymerase chain reaction based analysis of the cytotoxin associated gene pathogenicity island of *Helicobacter pylori* from saliva: an approach for rapid molecular genotyping in relation to disease status. J Gastroenterol Hepatol 2005: **20**: 1560–1566.
32. Umeda M, Kobayashi H, Takeuchi Y et al. High prevalence of *Helicobacter pylori* detected by PCR in the oral cavities of periodontitis patients. J Periodontol 2003: **74**: 129–134.
33. Victoria JM, Kalapothakis E, Silva Jde F, Gomez RS. *Helicobacter pylori* DNA in recurrent aphthous stomatitis. J Oral Pathol Med 2003: **32**: 219–223.
34. Young KA, Allaker RP, Hardie JM. Morphological analysis of *Helicobacter pylori* from gastric biopsies and dental plaque by scanning electron microscopy. Oral Microbiol Immunol 2001: **16**: 178–181.